From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board
Targeted Oncology · 2026-07 · 21 (4) · 593-608
DOI: 10.1007/s11523-026-01231-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Targeted Oncology, online erschienen am 17.07.2026. Verfasst von Tabea Fröhlich und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center for Personalized Medicine (Zentrum für Personalisierte Medizin, ZPM), Comprehensive Cancer Center (CCC) Hannover (Claudia von Schilling Center…. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).
Abstract (Originalsprache)
BACKGROUND: Molecular tumor boards (MTBs) support precision oncology by translating genomic profiling into evidence-based treatment recommendations, for example according to the European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets (ESCAT). Their clinical utility in real-world care depends on effective implementation within healthcare systems. OBJECTIVES: To evaluate the implementation rate of MTB recommendations, associated determinants, and clinical outcomes in a real-world single-center cohort. PATIENTS AND METHODS: At a single-center MTB, 582 consecutive cases (2020-2023) were retrospectively analyzed, with last survival follow-up in August 2025. Patient demographics, tumor characteristics, genomic alterations, ESCAT and ZPM (Zentrum für Personalisierte Medizin) evidence levels, targeted therapy recommendation and implementation rates, survival outcomes, and barriers to implementation were evaluated using descriptive and inferential statistics, as appropriate. RESULTS: Of 582 patients (median age 61 years, 48.5% female, 78.2% UICC stage IV), 55.6% (n = 324) received a targeted therapy recommendation, most based on ESCAT I-II evidence (59.9%). Among patients with a therapy recommendation, implementation status was unknown in 83 cases, but at least 23.5% (n = 76) received the proposed therapy. Major barriers included continuation of alternative systemic therapy (n = 89, 53.9%) and best supportive care or death before initiation (n = 54, 32.7%). Stronger levels of evidence (ESCAT per level increase: OR 1.22, 95% CI 1.08-1.39, p = 0.003; ZPM per level increase: OR 1.43, 95% CI 1.19-1.75, p < 0.001) and lower gastrointestinal cancer (OR 2.39, 95% CI 1.13-4.93, p = 0.020) were positively associated with increased likelihood of therapy implementation, while extramural molecular profiling showed a trend toward lower uptake (OR 0.61, 95% CI 0.36-1.03, p = 0.062). Overall survival (OS) from the date of MTB discussion in the full cohort (n = 563) was 11.1 months (95% CI 9.7-12.8). In patients who received at least one prior therapy before MTB discussion (n = 202), OS was 20.1 months (95% CI 12.3-NA) in patients who received the MTB-recommended therapy (n = 62) versus 7.7 months (95% CI 6.5-12.5) in those who did not (n = 140; p < 0.001). Among 31 patients with paired data, PFS under MTB-guided therapy was significantly longer than in the prior line (p = 0.036), with 54.8% achieving a PFS2/PFS1 ratio ≥ 1.3. CONCLUSIONS: In this real-world analysis, implementation of MTB recommendations was associated with improved survival outcomes. However, systemic, clinical, and logistical barriers substantially limited uptake. Earlier integration of MTBs into treatment planning and targeted strategies to address these barriers may help increase their potential benefit for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Center for Personalized Medicine (Zentrum für Personalisierte Medizin, ZPM), Comprehensive Cancer Center (CCC) Hannover (Claudia von Schilling Center), Hannover Medical School, Hannover, Germany.
- Department of Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School, Hannover, Germany.
- PRACTIS Clinician Scientist Program, Dean's Office for Academic Career Development, Hannover Medical School, Hannover, Germany.
- Institute of Pathology, Hannover Medical School, Hannover, Germany.
- Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
- Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
Förderung
- Medizinische Hochschule Hannover (MHH)
Zitieren
APA
Fröhlich, T., Lehmann, U., Reineke-Plaaß, T., Wirth, T., Welland, S., Du, C., Auber, B., Bollmann, B. A., Ivanyi, P., Park-Simon, T. W., Steinmann, D., Hartmann, C., de Oliviera Mekonnen, A., Heutling, A., Schütte, A., Wedemeyer, H. H., Heidel, F. H., Isfort, S., Vogel, A., & Saborowski, A. (2026). From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board. Targeted Oncology, 21(4), 593-608. https://doi.org/10.1007/s11523-026-01231-2
Vancouver
Fröhlich T, Lehmann U, Reineke-Plaaß T, Wirth T, Welland S, Du C, et al. From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board. Targeted Oncology. 2026;21(4):593-608. doi:10.1007/s11523-026-01231-2
BibTeX
@article{Frhlich2026,
author = {Fröhlich, Tabea and Lehmann, Ulrich and Reineke-Plaaß, Tanja and Wirth, Thomas and Welland, Sabrina and Du, Chen and Auber, Bernd and Bollmann, Benjamin-Alexander and Ivanyi, Philipp and Park-Simon, Tjoung-Won and Steinmann, Diana and Hartmann, Christian and de Oliviera Mekonnen, Ariana and Heutling, Anja and Schütte, Andrea and Wedemeyer, Hans Heinrich and Heidel, Florian Heinrich and Isfort, Susanne and Vogel, Arndt and Saborowski, Anna},
title = {From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board},
journal = {Targeted Oncology},
year = {2026},
volume = {21},
number = {4},
pages = {593--608},
doi = {10.1007/s11523-026-01231-2}
}
EUVIMED